Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
12 results loaded, newest first. End of these results.
U.S. stocks are higher at midday Wednesday, led by technology and software shares, after softer-than-expected inflation data eased fears of another Federal Reserve rate hike. Oil is climbing again, however, and long-dated Treasury yields remain close to multi-decade highs. • United Therapeutics stock is charging ahead
FTSE 100 rose 0.34% to 10,721.48 by 0925 GMT, with pharma shares up after AstraZeneca agreed a $2 billion stake in Summit Therapeutics.
The companies also agreed to a clinical trial collaboration to evaluate ivonescimab with sonesitatug vedotin in gastrointestinal cancers. Summit said AstraZeneca’s investment will be in convertible preferred shares.
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
FTSE 100 was little changed Tuesday: declines in pharma, consumer and banking were offset by gains in commodity-related shares. UK retail sales rose 0.7% in August, below the 1.6% 12-month average.
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
AstraZeneca shares rise 3%
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company. The combined business will operate as Supernus and trade on the Nasdaq Global Market
AstraZeneca Plc (NASDAQ: AZN ) on Monday posted mixed second-quarter 2026 results, beating Wall Street’s earnings estimates while falling short on revenue. The drugmaker also reported disappointing late-stage trial results for two experimental therapies, including a Phase 3 study of Ultomiris. AstraZeneca Beats Earning
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc (NYSE: AZN ) to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC). The partnership follows regulatory clearance in China for a Phase 1/2 s
On Sunday, AstraZeneca Plc (NYSE: AZN ) reported positive late-stage data for investigational therapy efzimfotase alfa in children with hypophosphatasia (HPP), while separately securing European Union approval for cancer drug Enhertu in a broad group of HER2-positive solid tumors, marking two significant milestones acr